title: Rituximab used in three cases with relapsed non-Hodgkin's lymphoma.
abstract: Relapsed or refractory B-cell non-Hodgkin's lymphoma (B-NHL) patients have a poor prognosis. New treatment modalities have been used to improve survival rates in children with relapsed or refractory B-NHL. CD20 is expressed in >98% of childhood B-NHL and a chimeric anti-CD20 monoclonal antibody, rituximab, is increasingly being used at relapse. The aim of the present study was to determine the efficacy of rituximab on relapsed B-NHL. Three B-NHL cases were treated successfully with a combination of intensive chemotherapy protocol plus rituximab.
authors.affiliation: Departments of Pediatric Hematology/Oncology, Ondokuz Mayıs University, Faculty of Medicine, Samsun 55220, Turkey.
authors.forename: Murat
authors.initials: M
authors.lastname: Elli
authors.affiliation: Departments of Pediatric Hematology/Oncology, Ondokuz Mayıs University, Faculty of Medicine, Samsun 55220, Turkey.
authors.forename: Sema
authors.initials: S
authors.lastname: Yilmaz
authors.affiliation: Radiology, Ondokuz Mayıs University, Faculty of Medicine, Samsun 55220, Turkey.
authors.forename: Ramazan
authors.initials: R
authors.lastname: Aydin
authors.affiliation: Pediatrics, Ondokuz Mayıs University, Faculty of Medicine, Samsun 55220, Turkey.
authors.forename: Sadriye
authors.initials: S
authors.lastname: Murat
authors.affiliation: Radiology, Ondokuz Mayıs University, Faculty of Medicine, Samsun 55220, Turkey.
authors.forename: Meltem Ceyhan
authors.initials: MC
authors.lastname: Bilgici
authors.affiliation: Departments of Pediatric Hematology/Oncology, Ondokuz Mayıs University, Faculty of Medicine, Samsun 55220, Turkey.
authors.forename: Ayhan
authors.initials: A
authors.lastname: Dagdemir
keywords: children; non-Hodgkin’s lymphoma; relapse; rituximab